Embecta (EMBC) vs Pro-Dex (PDEX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pro-Dex (PDEX) has outperformed Embecta (EMBC) over the past year, gaining 91.3% versus a loss of 57.1%. Embecta is the larger company by market cap ($334.9 million vs $203.0 million), about 1.6 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 18.7x for Pro-Dex).
Embecta pays a dividend yielding 7.78%, while Pro-Dex does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | PDEX |
|---|---|---|
| Share price | $5.91 | $62.80 |
| Market cap | $334.86M | $203.05M |
| 1-day change | -0.67% | -3.27% |
| YTD return | -50.25% | +63.20% |
| 1-year return | -57.11% | +91.35% |
| 5-year return | — | +144.26% |
| P/E ratio (TTM) | 4.02 | 15.24 |
| Forward P/E | 3.35 | 18.69 |
| EPS (TTM) | $1.47 | $4.12 |
| Dividend yield | 7.78% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $77.00 |
| 52-week low | $2.77 | $23.47 |
| Distance from 52-week high | -60.36% | -18.44% |
| Analyst consensus | none | none |
| Avg. price target upside | -32.32% | +17.83% |
| Average volume | 1.37M | 81.57K |
| Shares outstanding | 56.66M | 3.23M |
| Employees | 1,850 | 201 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDEX has outperformed EMBC by 148.5 percentage points over the past year.
- Pro-Dex trades at a higher earnings multiple (15.2x vs 4.0x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (7.78% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About Pro-Dex
PDEX stock →Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide.
Health Care · Medical/Dental Instruments · 201 employees
EMBC vs PDEX FAQ
Which is bigger, Embecta or Pro-Dex?
Embecta (EMBC) is larger, with a market capitalization of $334.86M compared with $203.05M for Pro-Dex (PDEX).
Which stock has performed better over the past year, EMBC or PDEX?
PDEX returned +91.35% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EMBC or PDEX?
EMBC has the lower trailing P/E at 4.0, versus 15.2 for PDEX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Embecta or Pro-Dex?
Embecta pays a dividend yielding 7.78%, while Pro-Dex does not currently pay a regular dividend.
Are Embecta and Pro-Dex in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.